Inozyme Total Cash From Financing Activities from 2010 to 2025

INZY Stock  USD 1.50  0.02  1.32%   
Inozyme Pharma Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities will likely drop to about 74.1 M in 2025. During the period from 2010 to 2025, Inozyme Pharma Total Cash From Financing Activities regression line of annual values had r-squared of  0.34 and arithmetic mean of  54,912,567. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2019-03-31
Previous Quarter
458 K
Current Value
10.5 M
Quarterly Volatility
31.8 M
 
Covid
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.9 M, Interest Income of 4.9 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.49. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
  
Check out the analysis of Inozyme Pharma Correlation against competitors.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Inozyme Pharma over the last few years. It is Inozyme Pharma's Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
       Timeline  

Inozyme Total Cash From Financing Activities Regression Statistics

Arithmetic Mean54,912,567
Geometric Mean35,757,934
Coefficient Of Variation83.52
Mean Deviation36,619,279
Median31,945,000
Standard Deviation45,862,180
Sample Variance2103.3T
Range149.2M
R-Value0.59
Mean Square Error1477.1T
R-Squared0.34
Significance0.02
Slope5,654,325
Total Sum of Squares31550.1T

Inozyme Total Cash From Financing Activities History

202574.1 M
2024144.9 M
2023126 M
202272.8 M
2021609 K
2020149.8 M
201923 M

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities144.9 M74.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.